SiMON-PRO-Hematology®: Digital techology for pharmacotherapeutic and patient reported outcomes monitoring in patients with hematologic malignancies

Introduction: Advances in hematologic malignancy treatment have improved survival, but patients often experience treatment-related toxicities. Traditional clinical follow-up often overlooks the patient's subjective experience, highlighting the need for integrated patient-reported outcome measures (PROMs). The primary objective of this study was to describe the design and implementation of the SiMON-PRO-Hematology® system, a comprehensive information tool supporting the pharmacotherapeutic follow-up of patients with hematological malignancies. A secondary objective was to detail the process for PROM collection. Methods: SiMON-PRO-Hematology was designed by a multidisciplinary team of pharmacists, hematologists, nurses, and software engineers. This group defined the functional requirements of the system, as well as the demographic, clinical, laboratory, and pharmacotherapeutic variables and disease-specific PROMs relevant to hematologic malignancies. The system was structured into three main areas: Clinical care (assistance), management, and research. No primary data were collected; therefore, ethical approval was not required. Results: SiMON-PRO-Hematology automates PROM collection via tablet devices completed independently by patients. The platform integrates PROMs with baseline clinical data and laboratory results, generates real-time alerts, and supports structured pharmaceutical interventions. Business intelligence tools enable analysis of patient evolution, treatment adherence, and cohort comparisons. Implementation allows standardized, longitudinal follow-up, enhancing detection of safety and effectiveness signals while streamlining workflows and minimizing documentation duplication. Unlike existing tools, SiMON-PRO-Hematology integrates independently reported PROMs within a broader, adaptable monitoring system tailored to diverse hematologic malignancies. Discussion: This approach ilustrates how a fully integrated digital platform is designed to potentially enhance the quality and efficiency of pharmaceutical care, providing a technical framework to support proactive interventions, longitudinal monitoring, and patient-centered outcomes.